[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100117883":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":45,"centralContacts":28,"locations":49,"responsibleParty":87,"collaborators":28,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":28,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":28,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":28,"overallStatus":110,"whyStopped":28,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"PF-02413873","EXPERIMENTAL","PF-2413873 active treatment",[13,14,15,16],"Drug: PF-02413873 100 mg QD","Drug: PF-02413873 1500 mg QD","Drug: PF-02413873 20 mg QD","Drug: PF-02413873 500 mg QD",{"label":18,"type":19,"description":18,"interventionNames":20},"Placebo","PLACEBO_COMPARATOR",[21],"Drug: PF-02413873 Placebo",[23,29,33,37,41],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","PF-02413873 100 mg QD","100 mg of PF-02413873 oral suspension once daily for 14 days",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"PF-02413873 1500 mg QD","1500 mg of PF-02413873 oral suspension once daily for 14 days",[9],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"PF-02413873 20 mg QD","20 mg of PF-02413873 oral suspension once daily for 14 days",[9],{"type":24,"name":38,"description":39,"armGroupLabels":40,"otherNames":28},"PF-02413873 500 mg QD","500 mg of PF-02413873 oral suspension once daily for 14 days",[9],{"type":24,"name":42,"description":43,"armGroupLabels":44,"otherNames":28},"PF-02413873 Placebo","PF-0241383 Placebo once daily for 14 days",[18],[46],{"name":47,"affiliation":5,"role":48},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[50,63,72,77],{"facility":51,"status":28,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":28},"Pfizer Investigational Site","New Haven","Connecticut","06511","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-72.92816,41.30815,{"lat":61,"lon":60},{"facility":51,"status":28,"city":64,"state":65,"zip":66,"country":55,"countryCode":56,"cosmosGeoPoint":67,"geoPoint":71,"contacts":28},"Overland Park","Kansas","66211",{"type":58,"coordinates":68},[69,70],-94.67079,38.98223,{"lat":70,"lon":69},{"facility":51,"status":28,"city":64,"state":65,"zip":73,"country":55,"countryCode":56,"cosmosGeoPoint":74,"geoPoint":76,"contacts":28},"66212",{"type":58,"coordinates":75},[69,70],{"lat":70,"lon":69},{"facility":51,"status":28,"city":78,"state":28,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":28},"Brussels","1070","Belgium","BE",{"type":58,"coordinates":83},[84,85],4.34878,50.85045,{"lat":85,"lon":84},{"type":28,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":88,"oldOrganization":89},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100117883","phase-1-a-study-to-investigate-how-the-body-handles-multiple-doses-of-pf-0243873-and-to-investigate-the-effect-of-pf-02413873-on-sex-hormone-levels-in-healthy-young-women-100117883",false,"NCT00800618","A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women","A Double Blind (3rd Party Open), Randomised, Placebo Controlled, Dose Escalating, Parallel Group Study To Investigate The Safety, Toleration, Pharmacology And Pharmacokinetics, Of Multiple Doses Of PF-02413873 In Healthy Female Subjects.","Inclusion Criteria:\n\n* Healthy women of childbearing potential with a regular menstrual cycle\n\nExclusion Criteria:\n\n* Evidence or history of any major disease\n* Pregnant or nursing women\n* Requirement for chronic medication",true,"FEMALE","18 Years","35 Years",{"count":102,"type":103},42,"ACTUAL","INTERVENTIONAL",[106],"PHASE1","The study will investigate how well multiple doses of PF-02413873 are tolerated by healthy young women, how the body handles multiple doses of PF-02413873 and which effect PF-02413873 has on sex hormones in healthy young women",[109],"Endometriosis","COMPLETED","2010-02-09",{"date":113,"type":114},"2010-02-10","ESTIMATED",{"date":116,"type":28},"2008-11",{"date":118,"type":103},"2009-06",{"name":5,"class":6},4]